Blueshift Asset Management LLC Makes New Investment in Humana Inc. (NYSE:HUM)

Blueshift Asset Management LLC purchased a new stake in Humana Inc. (NYSE:HUM) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 2,534 shares of the insurance provider’s stock, valued at approximately $803,000.

Several other hedge funds have also recently modified their holdings of HUM. Creative Financial Designs Inc. ADV lifted its holdings in Humana by 244.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after buying an additional 61 shares during the period. CarsonAllaria Wealth Management Ltd. grew its stake in Humana by 111.4% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after purchasing an additional 39 shares during the last quarter. Atwood & Palmer Inc. purchased a new position in Humana in the third quarter valued at about $29,000. Ashton Thomas Securities LLC purchased a new stake in shares of Humana during the third quarter valued at about $31,000. Finally, Your Advocates Ltd. LLP lifted its position in shares of Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after buying an additional 45 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Trading Up 0.4 %

Humana stock opened at $296.83 on Thursday. The firm has a market cap of $35.74 billion, a PE ratio of 26.29, a P/E/G ratio of 2.40 and a beta of 0.52. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $526.47. The stock’s 50 day simple moving average is $275.91 and its two-hundred day simple moving average is $330.00. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The business had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. Analysts anticipate that Humana Inc. will post 15.86 earnings per share for the current year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.19%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s dividend payout ratio (DPR) is presently 31.36%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Wells Fargo & Company reduced their price objective on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Stephens reaffirmed an “equal weight” rating and set a $250.00 price target on shares of Humana in a research report on Wednesday, October 9th. Piper Sandler cut Humana from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $392.00 to $274.00 in a research report on Thursday, October 3rd. Leerink Partnrs lowered Humana from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, UBS Group lowered their price target on Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a report on Friday, October 4th. Twenty investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Humana currently has an average rating of “Hold” and a consensus price target of $315.86.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.